+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 57 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and preliminary effectiveness of TQB2930 combined with chemotherapy, with or without bevacizumab, in people who have HER2-abnormally expressed, locally advanced or metastatic colorectal cancer that cannot be removed by surgery. This phase IbII clinical trial aims to better understand how these treatments work together to target cancer cells expressing the HER2 protein. The study is sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. and includes adult participants from 18 to 75 years old. Participants are randomly assigned to receive either TQB2930 injection plus chemotherapy and bevacizumab injection or TQB2930 injection plus chemotherapy alone. Chemotherapy drugs include oxaliplatin and capecitabine tablets or irinotecan hydrochloride injection with capecitabine tablets. TQB2930 targets HER2 proteins on tumor cells to reduce their growth, while bevacizumab works by blocking blood vessel formation that feeds tumors. Treatment continues until disease progression or other criteria are met. Throughout the study, participants undergo assessments such as measuring tumor response, monitoring adverse events, and collecting blood samples to analyze drug levels and immune responses. The main outcomes include determining the recommended dose for phase 2, safety monitoring from consent until 28 days after the last dose, and tracking objective response rates for up to 24 months. Secondary outcomes include survival rates, duration of response, and drug behavior in the body. Participants are monitored regularly during treatment and follow-up periods lasting up to two years.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
31 locations
S

Actively Recruiting

Esophageal squamous cell carcinoma ESCC is a common and deadly cancer in China, with many patients diagnosed at advanced stages. This study evaluates a combined treatment approach using induction immunochemotherapy followed by concurrent chemoradiotherapy, aiming to improve outcomes for patients with locally advanced, unresectable ESCC. Researchers also focus on using circulating tumor DNA ctDNA to monitor treatment response and predict tumor progression, as ctDNA changes can appear before imaging detects recurrence. Participants receive induction immunochemotherapy consisting of toripalimab combined with paclitaxel and cisplatin every three weeks for two cycles. This is followed by radical concurrent chemoradiotherapy with weekly paclitaxel and cisplatin for five cycles along with radiotherapy delivered five days per week. The study dynamically monitors ctDNA levels at several points before treatment, before chemoradiotherapy, after 20 radiotherapy fractions, and every three months after treatment completion. During the study, participants undergo regular assessments including blood tests for ctDNA analysis and monitoring of tumor status. The main outcome measured is progression-free survival at one year. Safety and efficacy are tracked throughout the treatment and follow-up periods. The total participation duration and timing of assessments are carefully planned to evaluate the treatment strategy and its correlation with patient prognosis.

Age: 18Years - 75YearsAll GendersPhase Not Applicable
2 locations
S

Actively Recruiting

Researchers are evaluating the safety, tolerability, how the body processes and responds to BGB-B2033, and its preliminary antitumor activity in adults with advanced or metastatic cancers including hepatocellular carcinoma, alpha-fetoprotein-producing gastric cancer, extragonadal yolk sac tumors, non-dysgerminomas, and glypican-3-positive squamous non-small cell lung cancer. The study aims to find the recommended dose for further research when BGB-B2033 is given alone or combined with tislelizumab, with or without bevacizumab. Participants will receive BGB-B2033 through intravenous infusion either alone or combined with tislelizumab and sometimes bevacizumab. The study includes several parts dose escalation and safety expansion of BGB-B2033 alone, combination treatments to determine safe doses and recommended doses for expansion, and dose expansion in specific groups including participants with hepatocellular carcinoma in Asia and the United States. During the study, participants will have regular assessments to monitor safety, side effects, how their body processes BGB-B2033, and whether their cancer responds to treatment. Researchers will track adverse events, the best dose, overall response rates, duration of response, disease control, progression-free survival, serum drug levels, and overall survival for up to about two years. Participants will be closely monitored throughout the study period.

Age: 18Years +All GendersPhase 1Phase 2
51 locations
P

Actively Recruiting

Researchers are evaluating the safety and effects of a medicine called Fosmanogepix for treating candidemia and invasive candidiasis, serious fungal infections caused by Candida species. This Phase 3 study compares Fosmanogepix with standard treatments to see if it works at least as well as current therapies. The trial involves adult patients diagnosed with these infections, aiming to assess treatment success and patient survival. Participants receive one of two treatments two-thirds get Fosmanogepix through an intravenous IV infusion daily at the clinic, with an option to switch to oral tablets if well enough to continue treatment at home. One-third receive the standard care of Caspofungin IV infusion followed by oral Fluconazole capsules. Matching placebos are used for blinding. Treatment can last up to 6 weeks depending on infection clearance and symptom improvement. During the study, participants undergo regular assessments including blood tests and monitoring for treatment success and safety. Researchers measure survival at 30 days and response rates at multiple time points, including after treatment ends and at a 6-week follow-up. The study tracks adverse events, lab abnormalities, and drug levels to evaluate safety and treatment effects. Total participation can last up to about 12.5 weeks with follow-up visits to monitor long-term outcomes.

Age: 18Years +All GendersPhase 3
146 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the immune response and safety of different doses of an adsorbed acellular pertussis two-component diphtheria-tetanus combined vaccine in people aged 10 years and older. This Phase II randomized, blinded, placebo-controlled study aims to better understand how the vaccine works to prevent pertussis whooping cough, diphtheria, and tetanus infections. Participants will receive an intramuscular injection of either a low dose vaccine, a high dose vaccine, or a placebo. The preferred injection site is the deltoid muscle of the upper arm. The study compares these three groups to assess immune responses and safety profiles. The vaccination is a single dose, and participants are monitored for 30 days following injection. During the study, participants will be evaluated for immune responses by measuring antibody levels against diphtheria, tetanus, pertussis toxin, and filamentous hemagglutinin 30 days after vaccination. Safety is assessed by recording any adverse events related to the treatment within the same period. Participants are required to complete follow-up visits and comply with the study protocol. The total study duration extends until August 2027, with primary outcome measurements completed by September 2026.

Age: 10Years +All GendersPhase 2
1 location
A

Actively Recruiting

Researchers are evaluating the safety and effectiveness of transarterial tirapazamine embolization TATE compared to conventional transarterial chemoembolization cTACE for patients with intermediate-stage hepatocellular carcinoma HCC, a type of liver cancer. This phase IIIII clinical trial aims to determine if TATE offers potential benefits over the current standard treatment, providing important insights for future care. The study is sponsored by Zhejiang Raygene Pharmaceuticals Co., Ltd and involves random assignment of participants to treatment groups. Participants will be randomly assigned to receive one of two treatments. The TATE group will receive a fixed dose of 35 mg tirapazamine injected into the artery feeding the tumor, followed by embolization using iodized oil, gelatin sponge, and contrast agent. The cTACE group will be treated with a mixture of iodized oil and 50 mg epirubicin, followed by embolization with gelatin sponge and contrast agent. Both treatments aim to block blood flow to the tumor and deliver therapy directly to the liver. The treatments are given as procedures involving catheter-based arterial injections. During the study, participants will be monitored for up to 36 months to assess progression-free survival as the primary outcome. Secondary outcomes include complete response rate, objective response rate, duration of complete response, and overall survival. Researchers will perform regular evaluations to track tumor response and patient health. Safety and treatment effects will be closely observed throughout the study period, ensuring participant well-being and thorough data collection.

Age: 18Years +All GendersPhase 2Phase 3
2 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
C

Actively Recruiting

Researchers are evaluating the efficacy and safety of ATG-022 compared to Investigators Choice treatment in participants with CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma who have received prior second-line systemic therapy. This Phase III, randomized, controlled, open-label study involves participants with unresectable locally advanced or metastatic disease who have progressed after at least second-line and no more than fourth-line systemic therapy. The study is based on positive earlier data and aims to compare ATG-022 monotherapy with commonly used chemotherapy options. Participants receive either ATG-022 monotherapy at a dose of 1.8 mgkg every 21 days one cycle or Investigators Choice chemotherapy, which includes either Docetaxel or Irinotecan. Docetaxel is administered at 75-100 mgm every 21 days, while Irinotecan is given at 125 mgm on days 1 and 8 every 21 days. The study uses a parallel design to compare these two treatment regimens. Throughout the trial, participants undergo tumor assessments at baseline and then every 6 weeks during treatment, followed by less frequent evaluations after 12 and 24 months until disease progression or death. Survival follow-up occurs every 3 months until death or study end. Researchers measure progression-free survival, overall survival, objective response rate, disease control rate, and duration of response. Laboratory tests and physical examinations are conducted to monitor organ function and safety. Participants remain in the study until disease progression, death, or study completion, with ongoing monitoring of their health.

Age: 18Years +All GendersPhase 3
131 locations
M

Actively Recruiting

Researchers are evaluating the agreement between four different test methods and a reference assay for MET overexpression in patients with untreated non-small cell lung cancer NSCLC. The study focuses on treatment-nave patients with unresectable locally advanced, metastatic, or recurrent NSCLC. It is a multicenter, prospective study sponsored by AstraZeneca, aiming to improve understanding of tumor gene profiling and MET concordance. Participants undergo next-generation sequencing NGS testing initially to determine their EGFR mutation status. Based on these results, participants are assigned to one of three cohorts those with specific EGFR mutations, those without actionable genomic alterations, and those with other actionable genomic alterations. Additional diagnostic tests such as MET IHC testing, PD-L1, and Her2 testing are performed for participants in the first cohort. During the study, participants provide tissue samples collected after diagnosis but before any antitumor treatment. The research team analyzes various biomarkers and treatment patterns up to 90 days after the last patient in. Participants are monitored through these tests and gene profiling to assess the concordance of different diagnostic methods. The total participation duration aligns with the study completion date in March 2027.

Age: 18Years +All GendersPhase Not Applicable
51 locations

1-10 of 57

1